Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes.
Takeshi MatsumuraTomoko MakabeSeiko UedaYuki FujimotoKayo SadahiroShiori TsuruyamaYuma OokuboTatsuya KondoEiichi ArakiPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)
UMIN Clinical Trials Registry (UMIN000041543).